Lanreotide
FDA ApprovedAlso known as: Somatuline, Somatuline Depot
Somatostatin AnalogLast reviewed: April 28, 2026
A long-acting somatostatin analog FDA-approved for acromegaly and gastroenteropancreatic neuroendocrine tumors. Administered as a deep subcutaneous depot injection once monthly.
Mechanism of Action
Binds primarily to somatostatin receptor subtypes 2 and 5 (SSTR2, SSTR5), inhibiting growth hormone secretion, reducing IGF-1 levels, and suppressing tumor growth in neuroendocrine tumors.
Common Uses
- Acromegaly
- Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- Carcinoid syndrome
Known Risks
- GI side effects (diarrhea, abdominal pain)
- Gallstones
- Injection site reactions
- Hyperglycemia
- Bradycardia
Regulatory Status
FDA-approved as Somatuline Depot (2007) for acromegaly and GEP-NETs. Administered as a deep subcutaneous injection in the gluteal region once every 4 weeks.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Deep subcutaneous injection
Typical Dose
60–120 mg
Frequency
Once every 4 weeks
Cycle Length
Ongoing
Administered by healthcare professional in the deep subcutaneous tissue of the gluteal region. Pre-filled syringe. Dose adjusted based on GH and IGF-1 levels.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.